BBIO logo

BridgeBio Pharma Inc. (BBIO)

$76.80

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BBIO

Market cap

$14.96B

EPS

-3.04

P/E ratio

--

Price to sales

17.92

Dividend yield

--

Beta

0.96779

Price on BBIO

Previous close

$77.36

Today's open

$76.74

Day's range

$74.75 - $77.10

52 week range

$62.50 - $93.42

Profile about BBIO

CEO

Neil Kumar

Employees

839

Headquarters

Palo Alto, CA

Exchange

Nasdaq Global Select

Shares outstanding

194800782

Issue type

Common Stock

BBIO industries and sectors

Healthcare

Biotechnology & Life Sciences

News on BBIO

Acoramidis Was Associated with Lower Risk of Worsening Heart Failure Versus Tafamidis in Real-World Study and Reduced Heart Failure Events Within One Month in ATTRibute-CM

PALO ALTO, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced that new Phase 3 ATTRibute-CM analyses and real-world evidence for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) were presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois, and the XX International Symposium on Amyloidosis (ISA) 2026 in Montevideo, Uruguay. At AHA 2026, BridgeBio had 2 moderated posters and 3 posters, and at ISA 2026, BridgeBio had 28 total abstracts accepted comprising 12 new poster presentations and 16 encore poster presentations. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

news source

GlobeNewsWire • Nov 17, 2026

news preview

BridgeBio Pharma, Inc. (BBIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript

BridgeBio Pharma, Inc. (BBIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026

PALO ALTO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced 28 abstracts on acoramidis in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) comprised of 12 new posters, seven encore poster presentations, and nine encore posters, will be shared at the XX International Symposium on Amyloidosis (ISA) 2026, taking place November 15-18, 2026, in Montevideo, Uruguay. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

news source

GlobeNewsWire • Nov 11, 2026

news preview

BridgeBio to Participate in November and December Investor Conferences

PALO ALTO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:

news source

GlobeNewsWire • Nov 9, 2026

news preview

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on November 5, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 80 new employees in restricted stock units for an aggregate of 147,578 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on November 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.

news source

GlobeNewsWire • Nov 6, 2026

news preview

BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026

PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two moderated posters and three posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM), along with one BridgeBio-supported poster presentation led by Abbott Laboratories, will be shared at the American Heart Association (AHA) Scientific Sessions 2026, taking place in Chicago, Illinois on November 6-9, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Should You Invest $1,000 in BridgeBio Pharma Right Now?

BridgeBio saw revenue climb by 193% year over year in the third quarter. The company's lead therapy is a heart drug, Attruby.

news source

The Motley Fool • Nov 2, 2026

news preview

What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call

BridgeBio Pharma NASDAQ: BBIO reported third-quarter revenue growth driven by sales of ATTR cardiomyopathy treatment Attruby and a one-time milestone tied to European partner Bayer's commercialization of Beyonttra. The company also outlined plans for three potential U.S. product launches over the next seven months, subject to Food and Drug Administration decisions.

news source

MarketBeat • Oct 30, 2026

news preview

BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 30, 2026

news preview

BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates

- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year). Loss from operations was $11.6 million, driven by increased revenue and a one-time $75.0 million BEYONTTRA sales milestone from Bayer. Cash, cash equivalents and marketable securities were $1.5 billion as of September 30, 2026, fully funding all three launches and expansion indications

news source

GlobeNewsWire • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in BridgeBio Pharma Inc.

Open an M1 investment account to buy and sell BridgeBio Pharma Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BBIO on M1